查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014340

持续残余疗法市场：按产品类型、治疗方法、应用和最终用户划分－2026-2032年全球市场预测

Continuous Renal Replacement Therapy Market by Product Type, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，连续性肾臟替代疗法 (CRRT) 市场价值将达到 167.5 亿美元，到 2026 年将增长至 181.3 亿美元，到 2032 年将达到 304.3 亿美元，复合年增长率为 8.89%。

主要市场统计数据
基准年 2025 167.5亿美元
预计年份：2026年 181.3亿美元
预测年份 2032 304.3亿美元
复合年增长率 (%) 8.89%

持续肾臟替代疗法的实施应重点关注临床需求、营运挑战和影响相关人员决策的策略重点。

随着临床适应症的不断扩大以及对体液、溶质和血流动力学稳定性进行精准管理的需求日益增长，连续性肾臟替代疗法（CRRT）已成为重症肾臟病治疗方法的基石。过去十年间，CRRT已从仅限于特定加护病房的专科治疗方法发展成为被各类医院广泛采用的主流重症治疗方法，并在肾臟病学、重症监护和急诊管理之间建立了新的联繫。本文不仅将CRRT定位为一项生命维持技术，更将其视为耗材、监测和治疗方法整合领域创新发展的平台。

临床实践、技术和营运方面的变革性变化正在将持续肾臟替代疗法重塑为以数据驱动、以患者为中心、一体化的护理路径。

在临床创新、材料科学进步以及医疗保健系统优先事项转变的推动下，连续性肾臟替代疗法（CRRT）领域正经历着一场变革。新型膜技术和输注管理系统正在改善溶质清除率和血流动力学耐受性，而数位化介面和远端监测工具则使得在不同的医疗环境中实现更一致的治疗成为可能。因此，医疗设备生态系统正从独立的单功能设备演变为集治疗、资料收集和决策支援于一体的整合平台。

评估 2025 年美国关税变化对持续性肾臟替代疗法 (CRRT) 的采购、供应链韧性和策略采购决策的累积影响。

美国将于2025年实施新的关税政策，将进一步增加CRRT相关产品的采购和供应策略的复杂性。关税调整会影响进口组件、组装依赖型系统以及通常从全球供应商采购的各种耗材。医疗系统采购团队必须权衡临床需求与关税和供应链路线变化可能导致的成本波动。

关键细分洞察显示了产品类型、模式、临床应用和最终用户环境如何结合起来决定临床优先事项和筹资策略。

精细的市场細項分析揭示了不同产品类型、治疗模式、临床应用和终端用户环境如何相互作用，从而影响临床实践和采购重点。基于产品类型，市场细分为CRRT配件、CRRT耗材和CRRT系统，每种产品都有独特的临床和操作考量。配件便于安装和感染控制，耗材决定每次治疗的成本和供应的连续性，而係统则决定治疗能力和互通性。基于治疗模式，市场被细分为血液透析滤过、血液透析、血液滤过和超过滤，治疗模式的选择反映了不同患者群体在溶质清除率、液体清除精度和血流动力学接受度之间的权衡。

关键区域洞察揭示了美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响采用、供应链策略和监管参与。

区域趋势对CRRT技术的应用模式、报销架构和供应链选择有显着影响。在美洲，临床网路和三级医疗中心致力于整合诊疗路径并投资培训，以支援先进的CRRT专案；而采购部门则优先考虑合约稳定性和库存管理，以降低关税造成的成本波动。欧洲、中东和非洲（EMEA）地区的情况则较为复杂，监管协调和多样化的报销机製造就了不同的市场准入路径。一些市场优先考虑与本地製造商建立伙伴关係以应对进口限制，而另一些市场则优先考虑循证医学证据的积累，以支持三级医疗中心采用CRRT技术。

关键的企业级洞察，展示了创新、供应链敏捷性和证据生成如何塑造整个 CRRT 生态系统的竞争差异化。

CRRT领域的竞争活动主要体现在两个面向：产品渐进式改善和平台差异化。成熟的医疗设备製造商不断改进泵浦、过滤器和接口，以提高安全性和易用性。同时，新兴企业和组件专家正在推出新型薄膜、抗凝血技术和数位化工具，以支持临床决策。随着企业拓展至邻近治疗领域、确保耗材供应链或整合数据分析能力，策略联盟、授权协议和选择性併购日益受到关注。

为产业领导者提供可操作的策略建议，以协调持续肾臟替代疗法的临床价值、价值链韧性和市场进入。

行业领导者应优先考虑一系列切实可行的策略，将临床价值与营运韧性和市场进入相结合。首先，投资于互通性和以用户为中心的设计，将透过减轻重症监护团队的认知和时间负担，并实现与电子健康记录和数据平台的无缝集成，从而加速产品应用。其次，建立区域製造地和建构战略经销伙伴，将降低关税风险并增强供应连续性，尤其对于常用耗材和一次性配件。第三，发展以结果为导向的证据包，将医疗设备的选择和治疗方案与具有临床意义的终点联繫起来，将有助于与保险公司和医院采购委员会合作。

为了确保分析的稳健性，我们采用了严格的跨学科调查方法，结合了初步临床访谈、二次文献综述和跨学科检验。

本调查方法采用跨学科方法，结合一手质性研究、二手文献整合和跨部门检验，以全面了解CRRT的现况。主要资讯来源包括与重症监护和肾臟病专科临床医生、供应链和采购经理、监管专家以及医疗设备和耗材製造商的高级管理人员进行的结构化访谈和讨论。这些对话提供了公开资讯来源无法完全涵盖的治疗利用模式、采购决策者和营运限制等方面的背景资讯。

整合临床、营运和政策见解，为 CRRT 解决方案的可操作决策和策略投资提供明确的展望。

总之，连续性肾臟替代疗法（CRRT）在现代重症监护中发挥着至关重要的作用，其发展受到快速的临床创新、不断变化的采购趋势以及不同地区政策环境的影响。产品层面的创新、治疗方法的选择以及特定应用的需求相互作用，为製造商和医疗系统创造了大量机会，以改善患者预后和提升营运效率。同时，价格波动和供应链的脆弱性凸显了策略性采购和立足本地的韧性对于确保持续获得​​维持生命治疗的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：持续残余疗法市场：依产品类型划分

  • CRRT配件
  • CRRT耗材
  • 连续性肾臟替代疗法系统

第九章：持续残余疗法市场：依治疗方式划分

  • 血液透析滤过
  • 血液透析
  • 血液过滤
  • 超过滤

第十章：持续残余疗法市场：依应用领域划分

  • 急性肾损伤（AKI）
  • 慢性肾臟病（CKD）
  • 药物过量和成瘾
  • 败血症和败血性休克

第十一章：持续残余疗法市场：以最终用户划分

  • 门诊部
  • 医院
    • 加护病房
    • 肾臟病学

第十二章：持续残余疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：持续残余疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：持续残余疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国持续性肾臟替代疗法市场

第十六章：中国持续性肾臟替代治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anjue Medical Equipment Co., Ltd.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bellco Srl
  • Biolight Co., Ltd.
  • Cytosorbents Corporation
  • Fresenius Medical Care AG & Co. KGaA
  • Full Medical Co., Ltd.
  • Genrui Biotech Co., Ltd.
  • Getinge AB
  • Guangzhou MeCan Medical Limited
  • Infomed SA
  • Jafron Biomedical Co., Ltd.
  • Kawasumi Laboratories, Inc.
  • Medica SpA
  • Medites Pharma Spol sro
  • Medtronic plc
  • Mindray Medical International Limited
  • Nikkiso Co., Ltd.
  • Ningbo David Medical Device Co., Ltd.
  • Outset Medical, Inc.
  • SWS Hemodialysis Care Co., Ltd.
  • Terumo Corporation
  • Toray Medical Co., Ltd.
Product Code: MRR-433AB1DC293A

The Continuous Renal Replacement Therapy Market was valued at USD 16.75 billion in 2025 and is projected to grow to USD 18.13 billion in 2026, with a CAGR of 8.89%, reaching USD 30.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.75 billion
Estimated Year [2026] USD 18.13 billion
Forecast Year [2032] USD 30.43 billion
CAGR (%) 8.89%

A focused introduction to continuous renal replacement therapy capturing clinical imperatives, operational pressures, and the strategic priorities driving stakeholder decision-making

Continuous renal replacement therapy has emerged as a keystone intervention in critical care nephrology, driven by expanding clinical indications and the need for precision management of fluid, solute, and hemodynamic stability. Over the past decade, CRRT has transitioned from a niche therapy reserved for select intensive care units to a mainstream critical care modality adopted across diverse hospital settings, creating new intersections between nephrology, critical care, and acute care operations. This introduction frames CRRT not only as a life-sustaining technology but also as a platform for innovation in consumables, monitoring, and modality integration.

Clinicians increasingly prioritize therapy personalization, aiming to align modality choices, anticoagulation strategies, and replacement fluid management with patient phenotypes and pathophysiology. Concurrently, health systems are balancing clinical outcomes with supply chain resilience and workforce competency, prompting greater institutional investment in training and standardized protocols. These converging forces underscore the importance of multidimensional analysis that considers clinical efficacy, operational feasibility, and economic sustainability. In the sections that follow, readers will find an integrated perspective on emerging technologies, regulatory influences, tariff impacts, segmentation dynamics, regional trends, competitive activity, and pragmatic recommendations designed to support leaders seeking to optimize CRRT delivery and planning.

Transformational clinical, technological, and operational shifts reshaping continuous renal replacement therapy into integrated data-driven and patient-centric care pathways

The CRRT landscape is undergoing transformative shifts propelled by clinical innovation, material science advances, and changes in health system priorities. New membrane technologies and fluid management systems are improving solute clearance profiles and hemodynamic tolerance, while digital interfaces and remote monitoring tools are enabling more consistent therapy delivery across varied care settings. As a result, device ecosystems are evolving from discrete, single-purpose machines into integrated platforms that combine therapy delivery with data capture and decision support.

Adoption patterns are also changing. Critical care teams are re-evaluating modality selection with a stronger emphasis on patient-centered criteria and real-world outcomes rather than solely technical specifications. Concurrently, supply chain strategies are shifting toward bundled procurement models that prioritize interoperability and lifecycle management. Regulatory oversight and standards of care are tightening, accelerating the uptake of technologies that demonstrate clear safety and usability benefits. Taken together, these shifts are reshaping competitive dynamics and creating opportunities for companies that can deliver clinically differentiated products, scalable training programs, and robust evidence of improved care processes and outcomes.

Assessing the cumulative impact of United States tariff changes on continuous renal replacement therapy procurement, supply chain resilience, and strategic sourcing decisions for 2025

The introduction of new tariff policies in the United States for 2025 has created an additional layer of complexity in the procurement and supply strategies for CRRT-related goods. Tariff adjustments have implications for imported components, assembly-dependent systems, and a range of consumables that are often sourced from global suppliers. Health system purchasing teams must now reconcile clinical imperatives with potential cost variability introduced by customs duties and supply chain re-routing.

These policy changes are incentivizing a reappraisal of domestic sourcing strategies, supplier diversification, and the negotiation of longer-term agreements to stabilize pricing and availability. Some manufacturers are accelerating regional manufacturing footprints or securing tariff classification reviews to mitigate duty exposure. In parallel, hospitals and group purchasing organizations are exploring hybrid sourcing models that combine local inventory buffers with strategic imports to manage episodic cost fluctuations. The net effect is a heightened emphasis on supply chain transparency, tariff risk assessment, and contract clauses that protect against sudden cost escalations, all while ensuring uninterrupted delivery of life-critical CRRT therapies.

Key segmentation insights demonstrating how product categories, modalities, clinical applications, and end-user settings together determine clinical priorities and procurement strategies

A nuanced segmentation analysis reveals how different product categories, modalities, clinical applications, and end-user settings interact to shape clinical practice and procurement priorities. Based on product type, the market is studied across CRRT Accessories, CRRT Consumables, and CRRT Systems, each presenting distinct clinical and operational considerations: accessories drive ease of set-up and infection control, consumables determine per-treatment economics and supply continuity, and systems define therapy capability and interoperability. Based on modality, the market is studied across Hemodiafiltration, Hemodialysis, Hemofiltration, and Ultrafiltration, with modality selection reflecting trade-offs among solute clearance, fluid removal precision, and hemodynamic tolerance in diverse patient profiles.

Based on application, the market is studied across Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), Drug Overdose & Poisoning, and Sepsis & Septic Shock, and each application imposes unique demands on session duration, anticoagulation protocols, and monitoring intensity. Based on end user, the market is studied across Ambulatory Care Centers and Hospitals, with the Hospitals segment further examined across Intensive Care Units and Nephrology Departments, highlighting differences in capital allocation, staffing competencies, and clinical governance. Synthesizing these dimensions clarifies where innovation will deliver the greatest clinical value and where procurement leaders should prioritize interoperability, consumable standardization, and staff training to reduce variability in outcomes and total cost of care.

Critical regional insights revealing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape adoption, supply chain strategy, and regulatory engagement

Regional dynamics materially influence adoption patterns, reimbursement frameworks, and supply chain options for CRRT technologies. In the Americas, clinical networks and tertiary care centers are focusing on consolidation of care pathways and investment in training to support advanced CRRT programs, while procurement groups emphasize contract stability and inventory management to mitigate tariff-driven cost volatility. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization and reimbursement variability create differentiated pathways for market entry, with some markets favoring local manufacturing partnerships to address import constraints and others prioritizing evidence generation to support adoption in tertiary centers.

Asia-Pacific features a mix of rapid capacity expansion and targeted technology adoption; growth is often concentrated in urban tertiary institutions that serve as hubs for clinical trials and protocol development. Across regions, cross-border partnerships, technology transfer agreements, and regional distribution strategies are becoming more important as manufacturers seek to align manufacturing footprints with demand centers and regulatory requirements. These regional contrasts underscore the need for tailored market approaches that reflect local clinical priorities, supply chain realities, and policy environments, while maintaining global standards of care and product quality.

Key company-level insights showing how innovation, supply chain agility, and evidence generation are shaping competitive differentiation across the CRRT ecosystem

Competitive activity in the CRRT field is characterized by a dual focus on incremental product improvements and platform-level differentiation. Established device manufacturers continue to refine pumps, filters, and interfaces to improve safety and usability, while emerging firms and component specialists are introducing novel membranes, anticoagulation technologies, and digital tools that augment clinical decision-making. Strategic collaborations, licensing arrangements, and selective M&A are notable as companies seek to expand into adjacent therapy areas, secure consumable supply chains, or integrate data analytics capabilities.

In response to clinical demand for reduced variability and improved outcomes, many organizations are investing in evidence generation programs that include usability studies, real-world data collection, and outcome-based partnerships with health systems. Supply chain resilience has become a competitive axis, with leaders differentiating through localized production, multi-sourcing strategies, and transparent traceability. Commercial models are also evolving, with subscription and service-oriented arrangements gaining traction among buyers who prioritize predictable lifecycle costs and integrated training and maintenance services. These dynamics favor companies with balanced portfolios that combine durable system-level offerings with modular consumable ecosystems and robust post-sale support.

Actionable strategic recommendations for industry leaders to align clinical value, supply chain resilience, and market access in continuous renal replacement therapy

Industry leaders should prioritize a set of actionable strategies that align clinical value with operational resilience and market access. First, investing in interoperability and user-centered design will accelerate adoption by reducing cognitive and time burdens on critical care teams and enabling seamless integration with electronic health records and data platforms. Second, establishing regional manufacturing or strategic distribution partnerships will mitigate tariff exposure and strengthen supply continuity, particularly for high-use consumables and single-use accessories. Third, developing outcome-focused evidence packages that link device choices and modality protocols to clinically meaningful endpoints will facilitate engagement with payers and hospital procurement committees.

Leaders should also adopt flexible commercial models that combine capital, consumable, and service elements to accommodate the diverse payment and procurement environments across regions. Finally, prioritizing clinician training programs and competency-assessment frameworks will reduce therapy variability and enhance perceived value among end users. By operationalizing these recommendations through coordinated R&D, commercial, and regulatory actions, companies can create defensible positions that respond to both clinical demands and evolving policy constraints.

A rigorous multidisciplinary research methodology combining primary clinical interviews, secondary literature review, and cross-functional validation to ensure analytic robustness

The research methodology integrates a multidisciplinary approach combining primary qualitative inquiry, secondary literature synthesis, and cross-functional validation to achieve a comprehensive view of the CRRT landscape. Primary inputs included structured interviews and consultations with clinicians specializing in critical care and nephrology, supply chain and procurement leaders, regulatory experts, and senior executives from device and consumable manufacturers. These engagements provided contextual insights into therapy use patterns, procurement decision drivers, and operational constraints that are not fully captured in publicly available sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, device labeling information, and industry publications to triangulate clinical efficacy, safety considerations, and technology capabilities. The analysis applied a segmentation framework that layered product type, modality, application, and end-user perspectives to identify areas of unmet clinical need and commercial opportunity. Synthesis and validation steps included expert review cycles and scenario testing to ensure findings are robust across different clinical settings and regional policy environments. Where appropriate, sensitivity checks and cross-references were used to reconcile divergent perspectives and strengthen the interpretability of conclusions.

Concluding perspective synthesizing clinical, operational, and policy insights to guide pragmatic decision-making and strategic investment in CRRT solutions

In summary, continuous renal replacement therapy occupies a pivotal role in modern critical care, shaped by rapid clinical innovation, evolving procurement dynamics, and regionally differentiated policy environments. The interplay between product-level innovation, modality selection, and application-specific requirements creates rich opportunities for manufacturers and health systems to enhance patient outcomes and operational efficiency. At the same time, tariff changes and supply chain vulnerabilities underscore the need for strategic sourcing and localized resilience to ensure continuous access to life-critical therapies.

Decision-makers should approach CRRT strategy with a holistic lens that balances clinical evidence, clinician usability, supply chain integrity, and flexible commercial models. By aligning R&D investments with real-world clinical needs and by strengthening partnerships across the care continuum, stakeholders can reduce variability in care delivery and create sustainable value. The integrated insights presented here are intended to support clinical leaders, procurement officers, and commercial strategists as they navigate competing priorities and implement pragmatic solutions that improve both patient outcomes and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Renal Replacement Therapy Market, by Product Type

  • 8.1. CRRT Accessories
  • 8.2. CRRT Consumables
  • 8.3. CRRT Systems

9. Continuous Renal Replacement Therapy Market, by Modality

  • 9.1. Hemodiafiltration
  • 9.2. Hemodialysis
  • 9.3. Hemofiltration
  • 9.4. Ultrafiltration

10. Continuous Renal Replacement Therapy Market, by Application

  • 10.1. Acute Kidney Injury (AKI)
  • 10.2. Chronic Kidney Disease (CKD)
  • 10.3. Drug Overdose & Poisoning
  • 10.4. Sepsis & Septic Shock

11. Continuous Renal Replacement Therapy Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Hospitals
    • 11.2.1. Intensive Care Units
    • 11.2.2. Nephrology Departments

12. Continuous Renal Replacement Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Continuous Renal Replacement Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Continuous Renal Replacement Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Continuous Renal Replacement Therapy Market

16. China Continuous Renal Replacement Therapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Anjue Medical Equipment Co., Ltd.
  • 17.6. Asahi Kasei Medical Co., Ltd.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Baxter International Inc.
  • 17.9. Bellco S.r.l.
  • 17.10. Biolight Co., Ltd.
  • 17.11. Cytosorbents Corporation
  • 17.12. Fresenius Medical Care AG & Co. KGaA
  • 17.13. Full Medical Co., Ltd.
  • 17.14. Genrui Biotech Co., Ltd.
  • 17.15. Getinge AB
  • 17.16. Guangzhou MeCan Medical Limited
  • 17.17. Infomed SA
  • 17.18. Jafron Biomedical Co., Ltd.
  • 17.19. Kawasumi Laboratories, Inc.
  • 17.20. Medica S.p.A.
  • 17.21. Medites Pharma Spol s.r.o.
  • 17.22. Medtronic plc
  • 17.23. Mindray Medical International Limited
  • 17.24. Nikkiso Co., Ltd.
  • 17.25. Ningbo David Medical Device Co., Ltd.
  • 17.26. Outset Medical, Inc.
  • 17.27. SWS Hemodialysis Care Co., Ltd.
  • 17.28. Terumo Corporation
  • 17.29. Toray Medical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)